- Home
- PBYI vs VIGL Comparison
PBYI vs VIGL Comparison
Compare PBYI & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- VIGL
- Stock Information
- Founded
- PBYI 2010
- VIGL 2020
- Country
- PBYI United States
- VIGL United States
- Employees
- PBYI N/A
- VIGL N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- VIGL Health Care
- Exchange
- PBYI Nasdaq
- VIGL Nasdaq
- Market Cap
- PBYI 176.1M
- VIGL 141.1M
- IPO Year
- PBYI N/A
- VIGL 2022
- Fundamental
- Price
- PBYI $2.25
- VIGL $3.42
- Analyst Decision
- PBYI Strong Buy
- VIGL Buy
- Analyst Count
- PBYI 1
- VIGL 5
- Target Price
- PBYI $7.00
- VIGL $16.60
- AVG Volume (30 Days)
- PBYI 390.7K
- VIGL 118.4K
- Earning Date
- PBYI 10-31-2024
- VIGL 08-13-2024
- Dividend Yield
- PBYI N/A
- VIGL N/A
- EPS Growth
- PBYI N/A
- VIGL N/A
- EPS
- PBYI 0.18
- VIGL N/A
- Revenue
- PBYI $219,143,000.00
- VIGL N/A
- Revenue This Year
- PBYI N/A
- VIGL N/A
- Revenue Next Year
- PBYI N/A
- VIGL N/A
- P/E Ratio
- PBYI $12.42
- VIGL N/A
- Revenue Growth
- PBYI N/A
- VIGL N/A
- 52 Week Low
- PBYI $2.13
- VIGL $2.47
- 52 Week High
- PBYI $7.73
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- PBYI 31.78
- VIGL 46.18
- Support Level
- PBYI $2.42
- VIGL $3.20
- Resistance Level
- PBYI $2.56
- VIGL $3.78
- Average True Range (ATR)
- PBYI 0.17
- VIGL 0.30
- MACD
- PBYI -0.02
- VIGL 0.03
- Stochastic Oscillator
- PBYI 3.88
- VIGL 36.67
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.